Physician profile
Warren Banta
NPI 1861695678
$32,579.93
in general payments reported to CMS, 2019-2025
70 companies · $6,397 in 2025
The $6,397 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,454 · 2020: $2,328 · 2021: $3,543 · 2022: $3,802 · 2023: $4,705 · 2024: $6,351 · 2025: $6,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Long Term Medical Supply Or Device Loan: $2,098 · Education: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,816.36 |
| Long Term Medical Supply Or Device Loan | $2,098.14 |
| Education | $538.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,776.97 | 2019-2025 | |
| Pfizer INC. | $2,857.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,720.74 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $1,449.17 | 2019-2025 | Erleada, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $1,182.87 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $1,015.53 | 2019-2025 | |
| Gilead Sciences, INC. | $1,008.73 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $974.04 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $857.57 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
| Lilly USA, LLC | $840.06 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Beigene USA, INC. | $816.28 | 2021-2025 | Brukinsa |
| Eisai INC. | $781.68 | 2019-2025 | |
| Sobi, INC | $732.99 | 2022-2025 | |
| Celgene Corporation | $711.71 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $702.65 | 2019-2023 | Imbruvica, Epkinly |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $533.43 | 2019-2025 | Xtandi |
| Abbvie INC. | $532.56 | 2019-2025 | Venclexta |
| Amgen INC. | $514.72 | 2019-2023 | Lumakras |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.17 | 2019-2025 | Gilotrif |
| Puma Biotechnology, INC. | $457.88 | 2019-2025 | Nerlynx |
| Glaxosmithkline, LLC. | $457.36 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Array Biopharma INC | $451.77 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $339.28 | 2022-2025 | Fotivda |
| Emd Serono, INC. | $336.03 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $313.05 | 2020-2025 | Xpovio |
| Incyte Corporation | $309.95 | 2019-2025 | Jakafi |
| Rigel Pharmaceuticals, INC. | $284.34 | 2019-2024 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $269.46 | 2025 | Brukinsa |
| Genentech USA, INC. | $269.16 | 2019-2025 | Polivy, Itovebi, Tecentriq Hybreza |
| Seagen INC. | $268.45 | 2019-2023 | Adcetris, Tukysa |
| Genzyme Corporation | $260.86 | 2019-2025 | |
| Daiichi Sankyo INC. | $240.00 | 2020-2024 | Enhertu |
| Sumitomo Pharma America, INC. | $232.33 | 2023-2025 | Orgovyx |
| Exelixis INC. | $227.72 | 2019-2024 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $219.32 | 2021-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $201.41 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Myovant Sciences INC. | $162.84 | 2021-2022 | |
| Clovis Oncology, INC. | $157.43 | 2019-2022 | |
| Kite Pharma, INC. | $140.61 | 2021-2025 | Yescarta |
| Dova Pharmaceuticals | $116.96 | 2020-2021 | |
| Adc Therapeutics America, INC. | $110.06 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $106.75 | 2019-2025 | Libtayo |
| Mirati Therapeutics, INC. | $102.37 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $99.73 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $90.33 | 2024-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $86.21 | 2021-2024 | |
| Legend Biotech USA INC. | $75.50 | 2024-2025 | Carvykti |
| Secura Bio, INC. | $68.01 | 2019-2024 | Copiktra |
| Tolmar Pharmaceuticals, INC. | $67.71 | 2022 | |
| Deciphera Pharmaceuticals INC. | $54.40 | 2022-2025 | Qinlock, Romvimza |
| Blueprint Medicines Corporation | $50.06 | 2023-2024 | Ayvakit |
| Taiho Oncology, INC. | $48.46 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $45.90 | 2024-2025 | Pyrukynd |
| Immunocore Limited | $39.23 | 2024 | Kimmtrak |
| Tesaro, INC. | $30.87 | 2019 | |
| Morphosys, US INC. | $30.14 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $25.09 | 2024 | |
| Tersera Therapeutics LLC | $24.28 | 2022 | |
| Verastem, INC. | $23.71 | 2019 | |
| Blue Earth Diagnostics | $22.09 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $19.10 | 2019 | |
| Boston Scientific Corporation | $18.95 | 2023 | Bodyguardian |
| Alnylam Pharmaceuticals INC. | $18.66 | 2022 | |
| Shield Therapeutics INC | $18.20 | 2025 | |
| Myriad Genetic Laboratories, INC. | $18.01 | 2021 | |
| Mylan Institutional INC. | $18.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.50 | 2024 | |
| Aurobindo Pharma USA, INC. | $14.95 | 2020 | |
| Foundation Medicine, INC. | $13.31 | 2019 | |
| Kyowa Kirin, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Banta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.